US prescription drug prices fall sharply
Analysis based on 10 articles · First reported Aug 18, 2026 · Last updated Aug 18, 2026
The decline in prescription drug prices could pressure pharmaceutical company revenues and margins, potentially affecting stock valuations in the sector. However, the impact is tempered by the fact that the CPI measure reflects pharmacy payments rather than consumer prices, and many factors beyond policy changes are at play.
New federal data shows U.S. prescription drug prices fell 0.8% in July and are down 3.1% from a year ago, the steepest year-over-year drop since 1963. President Donald Trump has taken credit, attributing the decline to his 'most favored nation' drug deals and the TrumpRx website. However, drug pricing experts say the drop is likely driven by a combination of factors, including generic and biosimilar competition, the Biden-era Inflation Reduction Act's United States — Medicare drug price negotiation program, and a new Trump administration policy lowering GLP-1 weight loss drug prices for certain United States — Medicare enrollees. The impact of the MFN deals and TrumpRx remains unclear, and experts caution that the CPI measure does not directly reflect consumer out-of-pocket costs. Senator Elizabeth Warren has questioned the United States — White House's claim of $700 million in savings from TrumpRx, noting that the site does not store patient information.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard